-
Science Sub-Journal: Total survival rate up to 80%! CRIS...
Time of Update: 2020-11-29
studies have shown that a single intra-brain injection of CRISPR LNP (sgPLK1-cLNP) in invasive in-place glioblastoma in mice can increase the gene editing rate in the body by about 70%, significantly reduce tumor growth, extend the medium survival by about 50%, and increase the overall survival rate to 30% (figure H below).
-
JCI: Study reveals why children are protected from new crown outbreaks
Time of Update: 2020-11-29
study found that children's lungs and respiratory endottor cells expressed relatively low levels of specifically recognizable sars-CoV-2.
Sucre said: "We found a significant increase in (TMPRSS2) expression with age, and we have observed this at both gene and protein levels.
-
Nat Med: Scientists have successfully used macro genome sequencing technology to quickly identify pathogens in human body fluids
Time of Update: 2020-11-29
16, 2020 // -- In a recent study published in the international journal Nature Medicine, scientists from the University of California and others found that macrogenome sequencing techniques could be u
-
The first new treatment in 60 years! GSK returning bile acid transporter inhibitor linerixibat treats bile depressive itching with remarkable efficacy!
Time of Update: 2020-11-29
GSK has plans to launch Phase 3 clinical studies in 2021, and linerixibat has the potential to become the first new treatment for PBC bile itching in 60 years.
-
Mol Cell: Reveals the molecular mechanisms by which cells collect and discard damaged proteins
Time of Update: 2020-11-29
16, 2020 // -- In a recent study published in the international journal Molecular Cell, scientists from the University of Massachusetts, Amster, and others revealed the molecular mechanisms of UCH37 e
-
Cell Rep: Scientists have found potential targets that could help develop new treatments for endometriosis
Time of Update: 2020-11-29
November 16, 2020 // -- In a recent study published in the international journal Cell Reports, scientists from Michigan State University and others identified a potential genetic target, or promising
-
Nat Cancer: There's hope for treating many types of cancer! A new type of immunotherapy has entered early clinical trials!
Time of Update: 2020-11-29
In the study, researchers revealed why previous attempts by scientists have failed, and they have developed a special antibody with no excess activity that produces a powerful anti-tumor response in mouse bodies, and are currently conducting clinical trials to test its potential and effectiveness against multiple types of cancer.
-
TCR therapy welcomed the first positive Phase 3 results and significantly improved the overall survival rate
Time of Update: 2020-11-29
Today, Immunocore announced that its innovative T-cell-to-patient (TCR) therapy achieved positive mid-term results in Phase 3 clinical trials, significantly increasing the total survival rate (OS) of cancer patients treated.
-
Sci Adv: Diabetics are more susceptible to glucobacteria
Time of Update: 2020-11-29
recent study, Richardson, Thurlow and other team members experimented with diabetic and non-diabetic mice and staphylococcus strains with or without additional transport proteins.
in diabetic mice, Staphylococcus acobacteria strains with four glucose transport proteins rapidly form biofilms and activate molecular pathways that make them more toxic.
-
PNAS: Research reveals new mechanisms for promoting tissue repair
Time of Update: 2020-11-28
"This study provides a basic understanding of how macroph.com ages regulate their response to pathogens to provide an effective but controlled inflammatory response and avoid damage to host tissue," said lead author Ricardo Irizarry-Caro of the Cincinnati Department of Child Immunobiology and senior author Dr. Chandrashekhar Pasare.
-
eLife interpretation! Oxidants may help slow down the aging process in cells!
Time of Update: 2020-11-28
Photo Source: Mikael Molin/Chalmers University of Technology In fact, researchers are now taking another step forward in understanding how oxidants really slow down the molecular mechanisms behind the body's aging process, which may help them with new research, such as finding drugs that stimulate antioxidant proteins or detecting whether other drugs that boost the body's oxidants can slow age-related diseases.
-
Science sub-journal interpretation! Does air pollution really make the COVID-19 epidemic even more deadly?
Time of Update: 2020-11-28
Air pollution and COVID-19 mortality in The United States: Strengths and lys of an ecological regression analysis, Science Advances 04 Nov 2020, doi:10.1126/sciadv.abd4049(2) Jeremy Jackson, Kip Hodges.
-
Is honey really good for your body's health?
Time of Update: 2020-11-28
Photo Source: CC0 Public Domain A tablespoon of honey contains 64 calories, contains no fiber, few vitamins, and has less protein; although daily consumption of honey is not ideal, researchers have now found that honey has some special medicinal properties, and studies have shown that honey may be a good choice for treating a child's nighttime cough (although it is not considered safe for children under one year of age).
-
Nat Med: How immune memory is formed during the recovery phase of new coronavirus infection
Time of Update: 2020-11-28
In this way, we believe that most people who survive SARS-CoV-2 infection have a protective effect on re-infection," explains Dr. Hoffman of the Second Department of Medicine at Freiburg University Medical Center.
-
Ebiomedicine: New research helps treat inflammation
Time of Update: 2020-11-28
NOVEMBER 19, 2020 // -- In a recent study, a team of researchers from WEHI found a new compound that blocks key inflammatory pathways, potentially paving the way for new treatments for a variety of diseases, including COVID-19.
-
New medicine for rare diseases! C3 inhibitor pegcetacoplan received FDA priority review: Phase 3 efficacy beats heavyweight C5 inhibitor Soliris
Time of Update: 2020-11-28
Recently, the company announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to a new drug application (NDA) for Pgcetacoplan (APL-2), a drug used to treat cystic sleep hemoglobinuria (PNH), which has been shown in clinical trials to raise PNH standards and hopefully redefine PNH treatment.
-
Structure: Crystallological studies have revealed that HCV drugs can help treat COVID-19
Time of Update: 2020-11-28
November 17, 2020 // -- A recent experiment led by researchers at the U.S. Department of Energy's Oak Ridge National Laboratory has determined that several hepatitis C drugs can inhibit the main protease of SARS-CoV-2, which is critical to the toxic reproduction of new coronary diseases.
-
The first condensate-collecting disease (CAD) hemolytic therapy drug! Sanofi supplement C1s inhibitor sutimlimab was rejected by the FDA!
Time of Update: 2020-11-28
November 18, 2020 // -- Sanofi recently announced that the U.S. Food and Drug Administration (FDA) has issued a full response letter (CRL) to Suttimlimab's Biological Products Licensing Application (BLA), a monoclonal antibody used to treat hemolysis in adult patients with primary coagulation disease (CAD).
-
Science: Reveals the mechanisms of super-powerful synthetic nanoantibodies and new coronavirus
Time of Update: 2020-11-28
, the authors tested the effectiveness of Class I and Class II nanoantibodies inhibiting the binding of fluorescently labeled SpikeS2P to HEK293 cells expressing ACE2 (Figure 1E).
strategy to prevent SARS-CoV-2 from entering the host cell is designed to block the interaction of ACE2-RBD.
-
The first BTK inhibitor to treat immunoplate plateroid reduction (ITP)! FDA grants Sanofi rilzabrutinib fast track eligibility!
Time of Update: 2020-11-28
Fast Track Qualification (FTD) is designed to accelerate drug development and rapid review for serious diseases to address critically unsolved medical needs in key areas.
addition to ITP, rilzabrutinib is currently in Phase 3 clinical treatment for herpes, an immunometric-mediated disease characterized by blisters in the mucous membranes and skin.
